Cargando…
Estrogen, estrogen receptors, and hepatocellular carcinoma: Are we there yet?
A protective role of the sex steroid hormone estrogen in hepatocellular carcinoma (HCC) was suggested a few decades ago according to clinical data showing higher HCC morbidity and mortality among males. Several recent studies further confirmed the anti-cancer effects of estrogen in the liver. Howeve...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757114/ https://www.ncbi.nlm.nih.gov/pubmed/29358876 http://dx.doi.org/10.3748/wjg.v24.i1.1 |
_version_ | 1783290805874589696 |
---|---|
author | Sukocheva, Olga A |
author_facet | Sukocheva, Olga A |
author_sort | Sukocheva, Olga A |
collection | PubMed |
description | A protective role of the sex steroid hormone estrogen in hepatocellular carcinoma (HCC) was suggested a few decades ago according to clinical data showing higher HCC morbidity and mortality among males. Several recent studies further confirmed the anti-cancer effects of estrogen in the liver. However, it remains to be identified how to exploit estrogen signalling within clinical settings for HCC treatment. There are several unresolved issues related to the estrogen pathway in liver cells. The main problems include the absence of a clear understanding of which estrogen receptor (ER) isoform is predominantly expressed in normal and malignant liver cells, the ER isoform expression difference between males and females, and which ER isoform should be targeted when designing HCC therapy. Some of those questions were recently addressed by Iyer and co-authors. The current editorial review critically analyses the study by Iyer et al (WJG, 2017) that investigated the expression of ER subtypes in liver samples collected from patients with a healthy liver, hepatitis C virus cirrhosis, and HCC. ER presence was evaluated in association with gender, intracellular localization, inflammation marker NF-κB, and proliferation-related effector cyclin D1. The study limitations and advantages are discussed in light of recent advances in the HCC and estrogen signalling areas. |
format | Online Article Text |
id | pubmed-5757114 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-57571142018-01-22 Estrogen, estrogen receptors, and hepatocellular carcinoma: Are we there yet? Sukocheva, Olga A World J Gastroenterol Editorial A protective role of the sex steroid hormone estrogen in hepatocellular carcinoma (HCC) was suggested a few decades ago according to clinical data showing higher HCC morbidity and mortality among males. Several recent studies further confirmed the anti-cancer effects of estrogen in the liver. However, it remains to be identified how to exploit estrogen signalling within clinical settings for HCC treatment. There are several unresolved issues related to the estrogen pathway in liver cells. The main problems include the absence of a clear understanding of which estrogen receptor (ER) isoform is predominantly expressed in normal and malignant liver cells, the ER isoform expression difference between males and females, and which ER isoform should be targeted when designing HCC therapy. Some of those questions were recently addressed by Iyer and co-authors. The current editorial review critically analyses the study by Iyer et al (WJG, 2017) that investigated the expression of ER subtypes in liver samples collected from patients with a healthy liver, hepatitis C virus cirrhosis, and HCC. ER presence was evaluated in association with gender, intracellular localization, inflammation marker NF-κB, and proliferation-related effector cyclin D1. The study limitations and advantages are discussed in light of recent advances in the HCC and estrogen signalling areas. Baishideng Publishing Group Inc 2018-01-07 2018-01-07 /pmc/articles/PMC5757114/ /pubmed/29358876 http://dx.doi.org/10.3748/wjg.v24.i1.1 Text en ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Editorial Sukocheva, Olga A Estrogen, estrogen receptors, and hepatocellular carcinoma: Are we there yet? |
title | Estrogen, estrogen receptors, and hepatocellular carcinoma: Are we there yet? |
title_full | Estrogen, estrogen receptors, and hepatocellular carcinoma: Are we there yet? |
title_fullStr | Estrogen, estrogen receptors, and hepatocellular carcinoma: Are we there yet? |
title_full_unstemmed | Estrogen, estrogen receptors, and hepatocellular carcinoma: Are we there yet? |
title_short | Estrogen, estrogen receptors, and hepatocellular carcinoma: Are we there yet? |
title_sort | estrogen, estrogen receptors, and hepatocellular carcinoma: are we there yet? |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757114/ https://www.ncbi.nlm.nih.gov/pubmed/29358876 http://dx.doi.org/10.3748/wjg.v24.i1.1 |
work_keys_str_mv | AT sukochevaolgaa estrogenestrogenreceptorsandhepatocellularcarcinomaarewethereyet |